GLP-1 SEMAInterpret the evidence
How researchers compared semaglutide tablets and injections across trials
2 numbered sourcesSource years 2026
Peptides are short amino-acid chains connected by peptide bonds. Their form can affect how much of a peptide reaches the bloodstream and what it does after arriving. Semaglutide is a modified peptide that activates the GLP-1 receptor. It is available in FDA-approved oral and injectable products with product-specific indications. A 2026 analysis asked how weight outcomes in two separate trials could inform a comparison of particular oral and injectable formulations. [1, 2]
The investigators used OASIS 4, a placebo-controlled trial of oral semaglutide, and STEP 1, a placebo-controlled trial of injectable semaglutide. Both enrolled adults with obesity or with overweight and a related complication and included lifestyle changes alongside the assigned treatments. Each study could directly compare its own semaglutide formulation with its own placebo. The 2026 analysis used placebo as a common comparison to estimate the difference between the formulations. This is called an indirect treatment comparison. [1]
In the analysis based on treatment assignment, the estimated difference in percentage weight change favored the injectable formulation by about one percentage point. The confidence interval ranged from a small advantage for oral semaglutide to a larger advantage for the injection. The authors interpreted the differences across weight outcomes as consistent with comparable efficacy. The analysis was an estimate across two trials. Nobody in those two original trials was randomized between the oral and injectable products. [1]
A common comparator is useful when the populations, follow-up and supporting care are sufficiently similar. It helps account for each trial’s placebo response. Differences that remain between the studies can still affect the estimate, including who enrolled and how missing measurements or treatment discontinuation were handled. The results apply to the particular formulations and study populations that were compared. They do not show that every oral and injectable product with semaglutide has the same effects. [1, 2]
The FDA label groups multiple forms of Wegovy in one document while giving separate indications for its injection and tablets. Both have specific approved uses in adults for weight management and cardiovascular risk reduction, and the injection has additional indications. That distinction illustrates why the formulation and patient population belong in any account of the evidence. The indirect comparison focused on average weight outcomes in two trials. The label answers a separate regulatory question about the products FDA approved. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
